Palo Alto, CA – According to filings with the U.S. Securities and Exchange Commission, 180 Life Sciences is raising $15,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, James Woody played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About 180 Life Sciences
180 Life Sciences is developing new treatments for one of the worlds biggest drivers of disease: inflammation. The company consists of three programs developing novel drugs for treating distinct inflammatory diseases. These programs are led by world-leading scientists at prestigious universities who have already developed blockbuster drugs and made ground-breaking discoveries in their fields. One of the programs is conducting a phase 2b/3 trial and expects its first results in Q4 2021. Other clinical trials are expected to begin by the end of 2021.

To learn more about 180 Life Sciences, visit http://180lifesciences.com/

Contact:
James Woody, Chief Executive Officer
650-507-0669
jwoody@180lifesciences.com
https://www.linkedin.com/in/james-woody-705b184/

SOURCE: http://www.intelligence360.io
Copyright (c) 2021 SI360 Inc. All rights reserved